TLDR A peptide can produce striking results in mice and later show little benefit in people. That is not unusual, and it does not necessarily mean anyone made a mistake. Animal studies answer an important question: what does this experimental molecule do in this animal model under these conditions? Human clinical research asks a related … Read more
TLDR A paper can be technically accurate and still be easy to misread. Suppose the headline says: “Peptide X reduced tumor growth by 60%.” That sounds impressive. But before deciding what it means, we need to know whether the experiment involved: a purified enzyme, a dish of cancer cells, a mouse xenograft, twenty patients, or … Read more
TLDR Retatrutide has now produced significant improvements in both glycemic control and body weight in peer-reviewed Phase 2 and Phase 3 trials involving people with type 2 diabetes. The 2023 Phase 2 study found A1C reductions of about 2 percentage points at the higher doses and weight loss approaching 17% after 36 weeks. The evidence … Read more
Updated September 4, 2026 Retatrutide is no longer a drug candidate supported by one or two promising trials. Eli Lilly has built a broad clinical development program around the investigational triple hormone receptor agonist, testing it across obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, obstructive sleep apnea, knee osteoarthritis, chronic low back pain, … Read more
Retatrutide’s Phase 3 results are now large enough that one number no longer describes the drug. Depending on which trial you look at, the highest-dose retatrutide group lost an average of about 20.8%, 22.6%, 28.3%, or 28.7% of body weight. Those differences are not contradictions. They come from four trials that studied very different people. … Read more
TLDR Retatrutide, tirzepatide, and semaglutide act on different combinations of metabolic hormone receptors. Semaglutide: GLP-1 receptor agonist. Tirzepatide: GIP + GLP-1 receptor agonist. Retatrutide: GIP + GLP-1 + glucagon receptor agonist. In separate obesity trials without diabetes, semaglutide produced about 14.9% average weight loss at 68 weeks in STEP 1, tirzepatide produced up to 20.9% … Read more
TLDR Retatrutide has produced unusually large reductions in liver fat in a peer-reviewed randomized Phase 2a substudy involving people with obesity or overweight and metabolic dysfunction-associated steatotic liver disease, or MASLD. Among 98 participants with at least 10% liver fat by MRI-PDFF, average relative liver-fat reductions after 24 weeks were 42.9%, 57.0%, 81.4%, and 82.4% … Read more
TLDR Retatrutide has produced some of the largest average weight reductions reported in randomized obesity-drug trials, but the evidence needs to be read carefully. The strongest peer-reviewed obesity result remains the 2023 Phase 2 trial: participants receiving 12 mg lost an average 24.2% of baseline body weight at 48 weeks. Higher doses produced greater weight … Read more
TLDR A peptide can contain only a few dozen amino acids and still trigger a complex series of events inside a cell. The first step is often deceptively simple: the peptide binds to a receptor. But understanding how peptides interact with receptors requires more than the familiar “lock and key” analogy. Receptors are dynamic proteins. … Read more
TLDR A useful peptide does not necessarily need to perform only one biological task. That idea was central to a 2018 study published in the Journal of Controlled Release. Researchers investigated a synthetic peptide called CB5005 that was designed to combine two potentially useful properties: it could help cargo cross cellular barriers, and it could … Read more
